Parenteral cephalosporin therapy in ambulatory care: Advantages and disadvantages

Drugs

Volumn 59, Issue SUPPL. 3, 2000, Pages 19-28

  Esposito, Silvano ^a,b  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b Clin Malat Infettive Osp Gesu M   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; CEFAZOLIN; CEFOTAXIME; CEFOTETAN; CEFOXITIN; CEFTAZIDIME; CEFTIZOXIME; CEFTRIAXONE; CEFUROXIME; CEPHALOSPORIN; CLINDAMYCIN; GENTAMICIN; OXACILLIN; PENICILLIN DERIVATIVE; PIPERAZINE; TOBRAMYCIN; VANCOMYCIN;

ABSCESS; AMBULATORY CARE; ANTIBACTERIAL ACTIVITY; BACTERIAL ARTHRITIS; BACTERIAL MENINGITIS; BACTERIAL PNEUMONIA; CHRONIC OBSTRUCTIVE LUNG DISEASE; COST BENEFIT ANALYSIS; DRUG PROGRAM; DRUG SELF ADMINISTRATION; DRUG TOLERABILITY; ENDOCARDITIS; HOME CARE; HUMAN; INJECTION PAIN; LOWER RESPIRATORY TRACT INFECTION; OSTEOMYELITIS; PATIENT COMPLIANCE; PELVIC INFLAMMATORY DISEASE; PHLEBITIS; REVIEW;

EID: 0033932210     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200059003-00003     Document Type: Review

References (40)

1. ACCP/SCCP Consensus Conference Committee. Definition for sepsis and organ failure and guidelines of innovative therapies in sepsis. Chest 1992; 101: 1644-55
2. Halls GA. The management of infections and antibiotic therapy: a European survey. J Antimicrob Chemother 1993; 31: 985-1000
3. Schaherg T, Gialdroni Grassi G, Huchon G, et al. An analysis of decisions by European general practitioners to admit to hospital patients with lower respiratory tract infections. Thorax 1996; 51: 1017-22
4. Huchon GJ, Gialdroni Grassi G, Leophonte P, et al. Initial antibiotic therapy for lower respiratory tract infection in the community: a European survey. Eur Respir J 1996; 9: 1590-5
5. Tice A. The importance of teamwork for outpatient parenteral antibiotic therapy. Int J Antimicrob Agents 1995; 5: 13-7
6. Tice A. Outpatient parenteral antibiotic therapy. Management of serious infections. Part I. Medical, socioeconomic, and legal issues. The team concept. Hosp Pract Off Ed 1993; 28 Suppl. 1: 6-10
7. Fine MJ, Smith DN, Singer DE. Hospitalisation decision in acquired pneumonia: a prospective cohort study. Am J Med 1990; 89: 713-9
8. Tice A. Growing pains in outpatient intravenous antibiotic therapy. Infect Dis Clin Pract 1992; 1: 74-7
9. Brown RB. Outpatient parenteral antibiotic therapy: management of serious infections. Part I. Medical, socioeconomic, and legal issues. Selecting the patient. Hosp Pract Off Ed 1993; 28 Suppl. 1: 11-5
10. Consensus Conference of Canadian Advisory Committee on Home i.v. Antibiotic Therapy. Toronto, Canada: November 11-12 1994
11. Bollettino Statistics IMS Health, 1996
12. Francioli P, Etienne J, Hoigne R, et al. Treatment of streptococcal endocarditis with single daily dose of ceftriaxone sodium for four weeks. Efficacy and outpatient treatment feasibility. JAMA 1992; 267 (2): 264-7
13. Stamboulian D, Bonvehi Anevalo C. Antibiotic management of outpatients with endocarditis due to penicillin susceptible streptococci. Rev Infect Dis 1991; 13 Suppl. 2: S160-3
14. Wilson WR. Ceftriaxone sodium therapy of penicillin G-susceptible streptococcal endocarditis JAMA 1992; 267: 279
15. Bradley JS. Outpatient parenteral antibiotic therapy. Management of serious infections. Part II. Amenable infections and models for delivery. Meningitis. Hosp Pract Off Ed 1993; 28 Suppl. 2: 15-9
16. Sweet RL. Outpatient parenteral antibiotic therapy. Management of serious infections. Part II. Amenable infections and models for delivery. Pelvic inflammatory disease. Hosp Pract Off Ed 1993; 28 Suppl. 2: 25-30
17. Eron LJ, Goldenberg RI, Poretz DM. Combined ceftriaxone and surgical therapy for osteomyelitis in hospital and outpatient setting. Am J Surg 1984; 148 (4): 1-4
18. Kunkel MJ, Iannini PB. Cefonicid in a once-daily regimen for treatment of osteomyelitis in an ambulatory setting. Rev Infect Dis 1984; 4: 865-9
19. Gilbert DN, Tice AD, Marsh PK, et al. Oral ciprofloxacin therapy for chronic contageous osteomyelitis caused by aerobic Gram-negative bacilli. Am J Med 1987; 82 Suppl. 4: 254-8
20. Jacoby GA. Antimicrobial resistant pathogens in the 1990s. Ann Rev Med 1996; 47: 169-79
21. Jacobs MR, Appelbaum PC. Antibiotic-resistant pneumococci. Rev Med Microbiol 1995; 6 (2): 77-93
22. Trowbridge JF. Outpatient parenteral antibiotic therapy. Management of serious infections. Part II. Amenable infections and models for delivery. Pneumonia and chronic lung disease. Hosp Pract 1993; 28 Suppl. 2: 20-4
23. Kuzemko JA. Home treatment of pulmonary infection in cystic fibrosis. Chest 1988; 94 Suppl. 2: S162-6
24. Strandvik B, Hjelte L, Malmborg AS, et al. Home intravenous antibiotic treatment of patients with cystic fibrosis. Acta Paediatr 1992; 81: 340-4
25. Williams DN. Home intravenous antibiotic therapy (HIVAT): indications, patients and antimicrobial agents. Int J Antimicrob Agents 1995; 5: 3-8
26. Tice AD. Experience with a physician-directed, clinic-based program for outpatient parenteral antibiotic therapy in the USA. Eur J Clin Microbiol Infect Dis 1995; 14: 655-61
27. Dagan R, Einhorn M. A program of outpatient parenteral antibiotic therapy for serious paediatric bacterial infections. Rev Infect Dis 1991; 13 Suppl. 2: 152-5
28. Bradley JS. Once daily ceftriaxone in the outpatient treatment of paediatric infections. Chemotherapy 1991; 37 Suppl. 3: 3-6
29. Bolettino Statistics IMS Health; Maggio, 1997
30. Goldstein FW, Pean Y, Gertner J, et al. Resistance to ceftriaxone and other beta-lactams in bacteria isolated in the community. Antimicrob Agents Chemother 1995; 39 (11): 2516-9
31. An international collaborative surveillance study of community-acquired bacterial LRTI pathogens: the Alexander Project. J Antimicrob Chemother 1996; 38: 1-155
32. Bassetti D, Fraschini F, Pozzi E, et al. Ceftriaxone: 10 anni di esperienza nella terapia delle infezioni respiratorie. Torino: Editore UTET, 1994: 49-69
33. Kunkel MJ. Outpatient parenteral antibiotic therapy. Management of serious infections. Part I. Medical, socioeconomic, and legal issues. Quality assurance. Hosp Pract Off Ed 1993; 28 Suppl. 1: 33-8
34. Milkovich G. Benefits of outpatient antibiotic therapy: to the individual, to institution, third party and society. Int J Antimicrob Agents 1995; 5: 27-31
35. Poretz DM, Woolard D, Eron LJ, et al. Outpatient use of ceftriaxone. A cost-benefit analysis. Am J Med 1984; 77 (4C): 77-83
36. Capri S. Aspetti farmacoeconomici della terapia con antibiotici iniettivi: confronto tra trattamento ospedaliero e domiciliare. Farmaci e Terapia 1994; IX (1): 48-54
37. Kunkel MJ, Tice AD, OPIVITA Study Group. Serious adverse events in outpatient parenteral antibiotic therapy: a prospective multicenter study [abstract]. Proc Infec Dis Soc Am 1995; 132: 1
38. Tice AD. Handbook of outpatient parenteral therapy. New York: Scientific American Inc., 1997: 43-55
39. Surber C, Ludin E, Fluckiger A, et al. Pain assessment after intramuscular injection. Arzneimittelforschung 1994; 44 (12): 1389-94
40. MacGregor RR. Overall clinical utility of the intramuscular treatment of imipenem-cilastatin. Chemotherapy 1991; 37 Suppl. 2: 53-7